Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 4/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL793722 | 0.98 | SYK (0.42) | SYKNOS2NCF1NOS1NOS3 | |
| SCHEMBL14092979 | 0.82 | SYK (0.38) | SYKKDM4ETRPA1CYP1A2P2RX1 | |
| SCHEMBL10104260 | 0.82 | RAPGEF4 (0.44) | SYKNOS2NOS1KDM4ETRPA1 | |
| SCHEMBL16810278 | 0.80 | ZAP70 (0.38) | SYKTRPA1CYP1A2P2RX1 | |
| SCHEMBL14117049 | 0.79 | CCR2 (0.39) | SYKNOS2NOS1KDM4ETRPA1 | |
| SCHEMBL18485039 | 0.78 | NOS2 (0.51) | SYKNOS2NCF1NOS1HRH3 | |
| SCHEMBL28735466 | 0.77 | LMNA (0.54) | CCR2TACR1 | |
| SCHEMBL14955274 | 0.75 | SYK (0.54) | SYKNOS2NOS1KDM4E | |
| SCHEMBL21203231 | 0.74 | KDM4E (0.37) | SYKNOS2NOS1NOS3KDM4E | |
| SCHEMBL22184066 | 0.74 | CCR2 (0.32) | SYKNOS2NOS1NOS3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | SYK 357/4885NOS2 2443/4885NCF1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.